The BDCP clinical study is for type 1 diabetes patients, 18 years or older, to evaluate the safety of LY3209590 in patients being treated with multiple daily injection therapy.
The SUNRISE study is a prospective, multi-center, double-blind, randomized, placebo-controlled trial in subjects aged 18.0 to <41.0 years diagnosed with T1D within 5 years.
The purpose of the 321 trial is to evaluate the safety of the Advanced Hybrid Closed Loop system (AHCL) in pediatric type 1 diabetes subjects age 7 – 13 in a home setting. The main objective in conducting this research is to collect data from patients who use the AHCL system at home, at work, […]
The Protect study will determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks.
The reason for this study is to compare a ultra-rapid lispro to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).
A 52-week study that compares the efficacy of Relamorelin with that of placebo in participants with diabetic gastroparesis with respect to the core signs and symptoms of diabetic gastroparesis.
Seeking Type 1 pediatric subjects who are interested in using a new Closed Loop pump system (Med 304). Open now to patients using a pump and sensor
Fill out the form below an we will let you know when a study becomes available that you may be interested in:
